A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

“…Despite the different underlying diseases, high-dose vitamin C showed a significant reduction in fatigue in almost all studies. The most recent study in patients with advanced lung cancer [ 21 ] is particularly compelling: while fatigue continued to increase in the control group despite the best supportive therapy, it decreased significantly in the group with vitamin C plus hyperthermia. The oncology studies mostly used the EORCT QOL-C30, which also examines physical and cognitive dysfunction, dyspnea, insomnia, and pain.…”

Section: Discussionmentioning

confidence: 99%

“…These complaints were also frequently alleviated by vitamin C. In cancer, very high doses of vitamin C are tested because of its chemotherapeutic potential. Three of the five oncology studies used doses >50 g [ 21 , 22 , 23 ]. In two studies, the dose was calculated based on body weight (bw) and ranged between 0.8 and 3 g vitamin C per kg bw [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue

Vollbracht

Kraft²

2021

Nutrients

View full text Add to dashboard Cite

Fatigue is common not only in cancer patients but also after viral and other infections. Effective treatment options are still very rare. Therefore, the present knowledge on the pathophysiology of fatigue and the potential positive impact of treatment with vitamin C is illustrated. Additionally, the effectiveness of high-dose IV vitamin C in fatigue resulting from various diseases was assessed by a systematic literature review in order to assess the feasibility of vitamin C in post-viral, especially in long COVID, fatigue. Nine clinical studies with 720 participants were identified. Three of the four controlled trials observed a significant decrease in fatigue scores in the vitamin C group compared to the control group. Four of the five observational or before-and-after studies observed a significant reduction in pre–post levels of fatigue. Attendant symptoms of fatigue such as sleep disturbances, lack of concentration, depression, and pain were also frequently alleviated. Oxidative stress, inflammation, and circulatory disorders, which are important contributors to fatigue, are also discussed in long COVID fatigue. Thus, the antioxidant, anti-inflammatory, endothelial-restoring, and immunomodulatory effects of high-dose IV vitamin C might be a suitable treatment option.

show abstract

“…More studies with more cases are needed to explore the combined treatment of mTOR inhibitor and mEHT. The following clinical advantages have been reported from this therapeutic principle: i) Very high heating efficiency for cancer with a low power (150 W) ( 34 ); ii) modulated electromagnetic waves do not result in burns on the skin ( 35 ), and ( 3 ) these waves adequately reach tumors deep within the body, such as those in the pancreas ( 36 ), lung ( 37 ), liver ( 32 ) and cervix ( 38 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer

et al. 2021

View full text Add to dashboard Cite

Modulated electro-hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance-matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for long-term therapy.

show abstract

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

Cited by 40 publications

References 43 publications

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study

Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue

Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer

Contact Info

Product

Resources

About